Health Care • Medical/Dental Instruments
$13.01 ▲ +0.08
(+0.62%)
MKT CAP: $446.6M • VOL: 104.6K
52W L $9 52W H $20
NPCE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $100.0M | $79.9M | $65.4M |
| YoY Revenue Growth % | +25.1% | +22.1% | — |
| Gross Profit | $77.2M | $59.1M | — |
| Gross Margin % | 77.2% | 73.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.3M | -$21.7M | -$27.2M |
| Operating Margin % | -16.3% | -27.1% | -41.5% |
| Net Income (GAAP) | -$21.5M | -$27.1M | -$33.0M |
| EBITDA (Normalized) | -$16.1M | -$21.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$11.0M | -$17.9M | -$19.7M |
| Capital Expenditures (CapEx) | $332.0K | $306.0K | — |
| Free Cash Flow (FCF) | -$11.3M | -$18.3M | -$19.7M |
| FCF Margin % | -11.3% | -22.8% | -30.1% |
| Return on Invested Capital (ROIC %) | -23.0% | -31.6% | — |
| Cash & Short-Term Equivalents | $21.7M | $13.4M | — |
| Total Debt (Short + Long Term) | $58.9M | $59.5M | — |
| Total Stockholders' Equity | $19.0M | $8.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NPCE.